Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Hao-Cheng Weng"'
Autor:
Hao-Cheng Weng, Chieh-Ju Sung, Jui-Ling Hsu, Wohn-Jenn Leu, Jih-Hwa Guh, Fan-Lu Kung, Lih-Ching Hsu
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Breast cancer is the most prevalent cancer and the second leading cause of cancer death in women. Cisplatin is a commonly used chemotherapeutic drug for breast cancer treatment. Owing to serious side effects, the combination of cisplatin with other d
Externí odkaz:
https://doaj.org/article/87867dc881c5485886ec66bb7c2bddb4
Publikováno v:
Frontiers in Pharmacology, Vol 10 (2019)
Breast cancer is the most commonly diagnosed cancer and the second leading cause of cancer death in women. Hormone receptor-positive breast cancer is usually subjected to hormone therapy, while triple-negative breast cancer is more formidable and pos
Externí odkaz:
https://doaj.org/article/3a50f21e63c74ef78a9a85f4b0c12b5b
Autor:
Huan-Yu Ku, Hao-Cheng Weng, Yen-An Shih, Po-Chen Kuo, Neill Lambert, Franco Nori, Chih-Sung Chuu, Yueh-Nan Chen
Publikováno v:
Physical Review Research, Vol 3, Iss 4, p 043083 (2021)
The Leggett-Garg inequality (LGI) distinguishes nonmacrorealistic channels from macrorealistic ones by constraining the experimental outcomes of the underlying system. In this work, we propose a class of channels which, initially, cannot violate the
Externí odkaz:
https://doaj.org/article/0e95ffd728b243eeb841ff2f8b056209
Autor:
Hao-Cheng Weng, 翁顥誠
107
Breast cancer remains within the top position when it comes to the cancer incidence and mortality rate worldwide. Cisplatin is a commonly used chemotherapeutic drug for breast cancer. However, owing to the serious side effects of cisplatin,
Breast cancer remains within the top position when it comes to the cancer incidence and mortality rate worldwide. Cisplatin is a commonly used chemotherapeutic drug for breast cancer. However, owing to the serious side effects of cisplatin,
Externí odkaz:
http://ndltd.ncl.edu.tw/handle/833gtf
Autor:
Franco Nori, Yueh-Nan Chen, Chih-Sung Chuu, Hao-Cheng Weng, Yen-An Shih, Neill Lambert, Po-Chen Kuo, Huan-Yu Ku
The Leggett-Garg inequality (LGI) distinguishes nonmacrorealistic channels from macrorealistic ones by constraining the experimental outcomes of the underlying system. In this work, we propose a class of channels which, initially, cannot violate the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::efcd5b0d6b52fcff72a87a3ad5f174af
Autor:
Tzu-En Huang, Paolo Marchetti, Maria Luisa Navacchia, Lih-Ching Hsu, Daniela Perrone, Elena Marchesi, Hao-Cheng Weng, Massimo L. Capobianco, Nicola Chinaglia, Jih-Hwa Guh
Publikováno v:
ChemMedChem (Internet) 14 (2019): 779–787. doi:10.1002/cmdc.201800756
info:cnr-pdr/source/autori:Elena Marchesi, Nicola Chinaglia, Massimo L. Capobianco, Paolo Marchetti, Tzu-En Huang, Hao-Cheng Weng, Jih-Hwa Guh, Lih-Ching Hsu, Daniela Perrone, Maria Luisa Navacchia/titolo:Dihydroartemisinin-bile acid hybridization as an effective approach to enhance dihydroartemisinin anticancer activity/doi:10.1002%2Fcmdc.201800756/rivista:ChemMedChem (Internet)/anno:2019/pagina_da:779/pagina_a:787/intervallo_pagine:779–787/volume:14
info:cnr-pdr/source/autori:Elena Marchesi, Nicola Chinaglia, Massimo L. Capobianco, Paolo Marchetti, Tzu-En Huang, Hao-Cheng Weng, Jih-Hwa Guh, Lih-Ching Hsu, Daniela Perrone, Maria Luisa Navacchia/titolo:Dihydroartemisinin-bile acid hybridization as an effective approach to enhance dihydroartemisinin anticancer activity/doi:10.1002%2Fcmdc.201800756/rivista:ChemMedChem (Internet)/anno:2019/pagina_da:779/pagina_a:787/intervallo_pagine:779–787/volume:14
A series of hybrid compounds based on natural products-bile acids and dihydroartemisinin-were prepared by different synthetic methodologies and investigated for their in vitro biological activity against HL-60 leukemia and HepG2 hepatocellular carcin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c4854de39a5ca780c93604d14bc345a
http://www.cnr.it/prodotto/i/401819
http://www.cnr.it/prodotto/i/401819